Martin Andreánsky
YOU?
Author Swipe
View article: Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy
Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy Open
Allogeneic hematopoietic cell transplantation (HCT) provides a curative option for patients with hemoglobinopathies by establishing donor-derived hematopoiesis. However, outcomes are compromised by toxicities and graft-versus-host disease …
View article: Long‐term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial
Long‐term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial Open
Peer Reviewed
View article: Lower limb dynamic stability in professional hockey players
Lower limb dynamic stability in professional hockey players Open
Introduction Ice hockey is one of the most popular sports that constitutes a physically demanding intermittent type of physical activity. It also requires an enormous amount of energy expended by the musculoskeletal system. The main object…
View article: Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease
Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease Open
Granulocyte colony-stimulating factor (G-CSF) used after hematopoietic stem cell transplantation (HSCT) can enhance neutrophil recovery in patients rendered neutropenic by the preparative regimen. G-CSF is contraindicated in patients with …
View article: Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients
Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients Open
Hematopoietic stem cell transplantation (HSCT) is a therapeutic option for many nonmalignant disorders (NMD) and is curative or prevents disease progression. Reduced-intensity conditioning (RIC) in HSCT for NMD may reduce regimen-related a…
View article: Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial
Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial Open
Allogeneic hematopoietic stem cell transplantation (HSCT) can cure transfusion-dependent thalassemia (TDT). In a multicenter trial we investigated the efficacy of reduced-intensity conditioning (RIC) before unrelated donor (URD) HSCT in ch…
View article: A trial of unrelated donor marrow transplantation for children with severe sickle cell disease
A trial of unrelated donor marrow transplantation for children with severe sickle cell disease Open
Key Points Children with sickle cell disease engrafted unrelated donor marrow after reduced intensity conditioning. A high incidence of GVHD and associated mortality compromised safety of the trial.
View article: Unrelated Donor Marrow (BMT) or Cord Blood Transplantation (UCBT) for Thalassemia Major after Reduced Intensity Conditioning (URTH Trial Extension)
Unrelated Donor Marrow (BMT) or Cord Blood Transplantation (UCBT) for Thalassemia Major after Reduced Intensity Conditioning (URTH Trial Extension) Open
Transplant cures thalassemia major (TM). If without related donors, unrelated (URD) BMT or UCBT are options. Myeloablation (MAC) is preferred for concerns of graft rejection (GR). URD BMT and UCBT publications describe 62-90% and 21-74% EF…